Cogent Biosciences
COGT
24 hedge funds and large institutions have $4.64M invested in Cogent Biosciences in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 4 closing their positions.
24% more capital invested
Capital invested by funds: $3.75M → $4.64M (+$893K)
0.67% more ownership
Funds ownership: 7.43% → 8.1% (+0.67%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 25 → 24 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$430K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$104K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$67.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.6K |
| 5 |
Barclays
London,
United Kingdom
|
+$3.47K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$55K |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$48.1K |
| 3 |
BlackRock
New York
|
-$18.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4K |
COGT Hedge Fund Activity: Q2 2020 in Review
24 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2020, worth a combined $4.64M — up 24% from $3.75M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of COGT and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $430K. The largest seller was Millennium Management, exiting entirely with an estimated $55K sold.
- 24 institutional investors held Cogent Biosciences (COGT) as of Q2 2020, down from 25 in Q1 2020.
- Funds reported $4.64M of Cogent Biosciences stock for Q2 2020, up 24% quarter-over-quarter.
- 3 funds opened new Cogent Biosciences positions in Q2 2020 and 4 closed out, a net change of -1 holder.
- The largest Cogent Biosciences buyer in Q2 2020 was Renaissance Technologies, an estimated $430K added.
- The largest Cogent Biosciences seller in Q2 2020 was Millennium Management, an estimated $55K sold.
Based on aggregated 13F filings for Q2 2020.